Has Baxter Healthcare Corporation had other FDA enforcement actions?

Yes. Argus HQ has recorded 229 total FDA actions tied to Baxter Healthcare Corporation: 0 warning letters, 229 recalls, 0 approval records, and 0 Form 483 inspection citations.

What kind of FDA record is this?

This is an Argus HQ record of a FDA Recall, tagged high severity by Argus HQ. FDA published the underlying record on 2026-09-09; Argus observed and indexed it on 2026-09-15.

Where can I verify this record directly with FDA?

The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

.hq

fda_recall · drug_recall · high

Baxter Healthcare Corporation — Class II recall: Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg…

Name: FDA Recall Record — Baxter Healthcare Corporation
Creator: Argus HQ
Published: 2026-09-09
License: https://argushq.ai/methodology

Event date: 2026-09-09 00:00:00Z
Observed: 2026-09-15 04:20:22Z
Source ID: D-0816-2026
Payload hash: c45d90c4b659f2e6ceae627b…

Summary

CGMP Deviations Status: Ongoing.

Entities

Baxter Healthcare Corporation

View source record ↗

Frequently asked questions

Has Baxter Healthcare Corporation had other FDA enforcement actions?: Yes. Argus HQ has recorded 229 total FDA actions tied to Baxter Healthcare Corporation: 0 warning letters, 229 recalls, 0 approval records, and 0 Form 483 inspection citations.
What kind of FDA record is this?: This is an Argus HQ record of a FDA Recall, tagged high severity by Argus HQ. FDA published the underlying record on 2026-09-09; Argus observed and indexed it on 2026-09-15.
Where can I verify this record directly with FDA?: The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Baxter Healthcare Corporation — Class II recall: Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg…. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0816-2026

MLA

"Baxter Healthcare Corporation — Class II recall: Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg…." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0816-2026.

Chicago

Argus HQ Research. "Baxter Healthcare Corporation — Class II recall: Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg…." Digital Empire Holdings LLC. Accessed September 15, 2026. https://argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0816-2026.

BibTeX

@misc{argushq_argushq_ai_events_fda_recall_baxter_healthcare_corporation_d_0816_2026_2026,
  title = {Baxter Healthcare Corporation — Class II recall: Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg…},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0816-2026},
  note = {Accessed: September 15, 2026}
}

Informational only. Not legal, financial, or medical advice.